KalVista Pharma Terminates KVD824 Phase 2 KOMPLETE Trial For Prophylactic Treatment Of HAE

RTTNews | Před 912 dny
KalVista Pharma Terminates KVD824 Phase 2 KOMPLETE Trial For Prophylactic Treatment Of HAE

(RTTNews) - KalVista Pharmaceuticals, Inc. (KALV) announced Monday that it has terminated the KOMPLETE phase 2 clinical trial for KVD824 for the prevention of attacks in people with hereditary angioedema (HAE).

This decision was based on the observation of liver enzyme (ALT/AST) elevations in multiple patients in all treatment groups of the trial. No patients had concomitant elevation of bilirubin levels and all were asymptomatic.

The KOMPLETE trial is a phase 2 clinical trial evaluating KVD824, an investigational oral plasma kallikrein inhibitor designed for the prevention of attacks in adults living with HAE.

Patients in the trial were randomized to one of three treatment groups, each placebo controlled: 300 mg, 600 mg, 900 mg KVD824 (or placebo), all dosed twice daily.

KalVista continues to recruit the phase 3 KONFIDENT trial assessing sebetralstat (formerly KVD900) as a potential oral, on-demand therapy for HAE attacks, with data anticipated in the second half of 2023.

For More Such Health News, visit rttnews.com

read more
KalVista Pharma Appoints Brian Piekos As New CFO

KalVista Pharma Appoints Brian Piekos As New CFO

KalVista Pharmaceuticals, Inc. (KALV) announced Tuesday that Brian Piekos has joined the Company as Chief Financial Officer (CFO). Piekos is an experienced public company CFO who brings a demonstrated track record of successfully leading companies across the biotechnology sector.
RTTNews | Před 205 dny
Malaysia Bourse May Give Up Support At 1,500 Points

Malaysia Bourse May Give Up Support At 1,500 Points

The Malaysia stock market has moved lower in two of three trading days since the end of the three-day winning streak in which it had picked up more than 30 points or 2 percent. The Kuala Lumpur Composite Index now sits just beneath the 1,520-point plateau and it may take further damage again on Friday.
RTTNews | Před 4 h 28 min
More Pain Predicted For Japan Stock Market

More Pain Predicted For Japan Stock Market

The Japanese stock market on Thursday ended the two-day winning streak in which it had picked up almost 110 points or 0.3 percent. The Nikkei 225 now rests just above the 34,735-point plateau and it may take further damage on Friday.
RTTNews | Před 4 h 58 min
South Korea Stock Market May Extend Losing Streak

South Korea Stock Market May Extend Losing Streak

The South Korea stock market has moved lower in two straight sessions, sinking almost 35 points or 1.4 percent along the way. The KOSPI now rests just above the 2,485-point plateau and it's likely to open under pressure again on Friday.
RTTNews | Před 5 h 28 min
Swiss Market Ends Sharply Lower On Tariff Woes

Swiss Market Ends Sharply Lower On Tariff Woes

Swiss stocks fell sharply on Thursday, in line with equities across the globe, as U.S. President Donald Trump's sweeping tariff announcement fueled inflation and growth concerns, prompting investors to exit counters.
RTTNews | Před 11 h 11 min